Calr plus Myelofibrosis/BCR-ABL Chronic Myeloid Leukemia Overlap Syndrome Treated with Asciminib

被引：1

作者：

Saal, Talia M. ^{[1
]}

Pellegrino, Christine ^{[2
]}

Ahmed, Tauseef ^{[2
]}

Seiter, Karen ^{[3
]}

Liu, Delong ^{[2
]}

Steinberg, Amir ^{[2
]}

机构：

[1] New York Med Coll, Valhalla, NY 10595 USA

[2] Westchester Med Ctr, Valhalla, NY USA

[3] Westchester Med Ctr, Larchmont, NY USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-184820

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] Frequency and Clonality of BCR-ABL Compound Mutations in Chronic Myeloid Leukemia [J].

Khorashad, Jamshid ;

Kelley, Todd W. ;

Szankasi, Philippe ;

Adrian, Lauren T. ;

Eide, Christopher A. ;

Zabriskie, Matthew S. ;

Lange, Thoralf ;

Kraft, Ira L. ;

Eiring, Anna M. ;

O'Hare, Thomas ;

Deininger, Michael W. .

BLOOD, 2011, 118 (21) :1598-1599

[42] BCR-ABL/ABL RATIO INCREASE THAT CORRESPONDS TOPRESENCEOFBCR-ABL MUTATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED BY IMATINIB [J].

Tsaur, G. ;

Ivanova, A. ;

Popov, A. ;

Yakovleva, Y. ;

Riger, T. ;

Ivanets, Y. ;

Misyurin, A. ;

Suchkova, M. ;

Shorikov, E. ;

Saveliev, L. ;

Fechina, L. .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 :S490-S490

[43] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate [J].

Jabbour, E. ;

Kantarjian, H. ;

Jones, D. ;

Talpaz, M. ;

Bekele, N. ;

O'Brien, S. ;

Zhou, X. ;

Luthra, R. ;

Garcia-Manero, G. ;

Giles, F. ;

Rios, M. B. ;

Verstovsek, S. ;

Cortes, J. .

LEUKEMIA, 2006, 20 (10) :1767-1773

[44] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate [J].

E Jabbour ;

H Kantarjian ;

D Jones ;

M Talpaz ;

N Bekele ;

S O'Brien ;

X Zhou ;

R Luthra ;

G Garcia-Manero ;

F Giles ;

M B Rios ;

S Verstovsek ;

J Cortes .

Leukemia, 2006, 20 :1767-1773

[45] ATP binding domain mutants of BCR-ABL in patients with chronic myeloid leukemia treated with imatinib. [J].

Liu, XL ;

Zhang, S ;

Du, QF ;

Fan, W ;

Wang, Y ;

Yao, F .

BLOOD, 2005, 106 (11) :294B-294B

[46] New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check [J].

O'Hare, Thomas ;

Eide, Christopher A. ;

Deininger, Michael W. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (06) :865-878

[47] BCR-ABL independent gene mutations in children and adolescents with chronic myeloid leukemia [J].

Busch, M. ;

Rinke, J. ;

Schaefer, V ;

Waldau, A. ;

Ernst, J. ;

Hochhaus, A. ;

Gruhn, B. ;

Ernst, T. .

ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 :53-54

[48] Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia [J].

Hyewon Lee ;

Igor Novitzky Basso ;

Dennis Dong Hwan Kim .

International Journal of Hematology, 2021, 113 :632-641

[49] Detection of BCR-ABL gene mutations in chronic myeloid leukemia using biochips [J].

A. Yu. Ikonnikova ;

Yu. E. Yatsenko ;

O. S. Kremenetskaya ;

O. V. Vinogradova ;

D. O. Fesenko ;

I. S. Abramov ;

V. A. Ovsepyan ;

T. V. Nasedkina .

Molecular Biology, 2016, 50 :412-416

[50] Detection of BCR-ABL fusion gene in diagnosis and treatment of chronic myeloid leukemia [J].

Zhou, Guidan ;

Xing, Shichao ;

Tian, Bingru ;

Chen, Youfen .

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (05) :3309-3315

← 1 2 3 4 5 →